Cannabis Law Report

JULY 26, 2021

OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has appointed Praveen Tyle, Ph.D., SAN DIEGO, CA, July 26, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. About Skye Bioscience.

Research and Development 105

Research and Development Clinical Trials Pharmaceutical Cannabinoids 105

Cannabis Law Report

MAY 10, 2022

The first in-depth study of Australia’s medicinal cannabis program, which began in 2016, shows the drug is being increasingly prescribed for various conditions. Since the beginning of the program, medicinal cannabis has been prescribed for over 140 conditions. The findings were published today in Frontiers in Pharmacology.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

NOVEMBER 22, 2021

Emyria was listed on the ASX last year, just before Australia was plunged into the global COVID-19 pandemic, and has been progressing with trials of a synthetic cannabinoid targeting mental health which it hopes to have registered domestically and in the American market.

Clinical Trials 52

Clinical Trials Treatment Medicine Cannabinoids 52

Cannabis Law Report

JANUARY 6, 2022

Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announced today that it has appointed Scott L. In this position, Mr. Anderson will be responsible for Anebulo’s global investor relations and public relations programs.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Programs 52

Cannabis Law Report

JUNE 17, 2021

As part of our continued R&D efforts we also look forward to advancing our PTSD and essential tremor programs, the nabiximols clinical trial program to support a U.S. regulatory approval, and our new cannabinoid research platform,” said Renée Galá, the chief financial officer of Jazz Pharmaceuticals.

Pharmaceutical 108

Pharmaceutical Clinical Trials Therapy Programs 108

Cannabis Law Report

MAY 10, 2022

Medicinal cannabis products such as capsules, creams, oils, lozenges, sprays and granulated flowers were approved for prescription 159,665 times between the start of Australia’s medicinal cannabis program in February 2016 and September 2021, research led by the University of Sydney’s Lambert Initiative for Cannabinoid Therapeutics shows.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Veriheal

MAY 26, 2022

Dedicated to “redefining what’s possible,” the 501(c)(3) organization has provided 1:1 support and resources to over 69,000 clients as they navigated plant-powered cannabinoid therapy. Patients around the world are in need of natural, alternative medical solutions, and Realm of Caring (RoC) is on a mission to serve them.

Advocacy 98

Advocacy Patients Clinical Trials Education 98

Veriheal

APRIL 11, 2022

He also emphasized the fact that medical cannabis programs are now legal in 37 states, as well as four out of five inhabited U.S. We could potentially develop north of 11,000 drugs that are cannabinoid-based. federal law, from which point, informed choices can be made about the use of cannabis and cannabinoids. territories.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

The Cannigma

MAY 19, 2021

Japan does not have a medical cannabis program and does not allow the use of cannabis for patients seeking to treat a medical condition. In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes.

Law 137

Law Legalization Clinical Trials CBD 137

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Commence clinical program in PTSD.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Puff Puff Post

JANUARY 13, 2020

Generally speaking, 99 cent stores sell CBD that doesn’t have its terpenes or other cannabinoids measured. So even when patients use CBD oil with essentially no THC, doctors need to understand a lot more about the complex chemical reactions of cannabinoids and terpenes. Preliminary Research on CBD Oil. Physicians at Mt.

CBD 52

CBD Clinical Trials Research and Development Oil 52

Puff Puff Post

JANUARY 13, 2020

Generally speaking, 99 cent stores sell CBD that doesn’t have its terpenes or other cannabinoids measured. So even when patients use CBD oil with essentially no THC, doctors need to understand a lot more about the complex chemical reactions of cannabinoids and terpenes. Preliminary Research on CBD Oil. Physicians at Mt.

CBD 52

CBD Clinical Trials Research and Development Oil 52

Cannabis Law Report

AUGUST 25, 2021

“Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies.

Clinical Trials 111

Clinical Trials Research and Development Therapy Conditions 111

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. Leading the pilot research project is Dr. Eric Hollander, director of the Autism and Spectrum Program and Anxiety and Depression Program at Montefiore Hospital.

Research and Development 94

Research and Development Epilepsy Clinical Trials Treatment 94

MedicalJane

JUNE 29, 2018

Food and Drug Administration (FDA) had approved only three cannabinoid-based medicines. percent of tetrahydrocannabinol (THC), the cannabinoid responsible for producing “high” psychoactive effects when consumed. Clinical trials show that Epidiolex significantly reduces seizure frequency. Prior to this week, the U.S.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Veriheal

AUGUST 31, 2020

Program between St. About Sinibaldo: Sinibaldo is an aspiring healthcare professional and a biomedical researcher in the Medical Scientist Training Program (M.D./Ph.D.) About Nishtha: Nishtha is pursuing neurology to become a physician-scientist in honor of her grandmother Nani who suffered from Alzheimer’s.

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

OCTOBER 5, 2021

The review excludes pre-clinical trials (i.e. Professor Mark Connor is a molecular pharmacologist with expertise in analgesics and psychoactive drugs, particularly cannabinoids and opioids, with extensive research experience in the USA, UK, and Australia. experimental pharmacology studies in test tube or animal models).

Treatment 52

Treatment Conditions Medicine Clinical Trials 52

TheAnswerPage

JANUARY 11, 2022

and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ In addition, if clinicians are not well informed about the health effects of cannabinoid-based products, clinicians will not be able to optimally treat their patients. million medical marijuana patients nationwide.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

JANUARY 24, 2022

Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

MAY 29, 2022

Clinical Trials and Human Subject Protections. Before the drug approval process even begins, sponsors must initiate clinical investigations by first filing an Investigational New Drug Application (IND) with FDA. FDA’s approval of an IND will also require sufficient evidence that the trial will be safe for human subjects.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

The Joint Blog

DECEMBER 27, 2020

According to a new study published in the peer-reviewed journal Cannabis and Cannabinoid Research (and also epublished by the National Institute of Health), those with post-traumatic stress disorder who consume marijuana display reduced symptoms over time compared to those who do not use marijuana at all.

Clinical Trials 49

Clinical Trials Marijuana Dispensary Treatment 49

CannaMD

AUGUST 8, 2020

In honor of National CBD Day, CannaMD wants to clear up some cannabinoid confusion once and for all. However, many of these products contain a number of other cannabinoids as well. To understand cannabinoids, we need to take a closer look at the endocannabinoid system.

CBD 99

CBD DEA Research and Development Hemp 99

Cannabis Law Report

JUNE 4, 2021

We support the Hemp Roundtable’s statements on psychoactive hemp and that it should be regulated separately from hemp, CBD, CBG and other non-psychoactive or non-intoxicating cannabinoids. Delta 8-THC is a psychoactive cannabinoid, just like Delta 9-THC, and legislators should regulate it as such.

Research and Development 105

Research and Development Seed-To-Sale Cannabinoids THC 105

Weedistry

JANUARY 28, 2019

Cannabinoid-derived product by Ontario-based Tetra Bio-Pharma to be officially recognized as a drug. It’s when presented with personal stories like that of the Rhodes family and the stream of alarming data that the significance of Tetra Bio-Pharma’s (TBP) clinical trials is worth exploring.

Clinical Trials 40

Clinical Trials Research and Development Chronic Pain Data 40

The Cannigma

JUNE 15, 2021

Cannabidiol (CBD) belongs to a class of molecules called cannabinoids , which are produced almost exclusively in cannabis — hence the name. The two cannabinoids can also cause very different effects in other ways. CBD is also often compared to CBG (cannabigerol) , another increasingly popular cannabinoid. CBD vs CBDA.

CBD 122

CBD Research and Development Epilepsy Extraction 122

MMJ Recs

DECEMBER 22, 2023

One of the key drivers of this shift is the increasing body of scientific research highlighting the medical properties of cannabinoids, the active compounds in marijuana. Over the past decades, numerous studies have investigated the medicinal properties of cannabinoids, the active compounds in marijuana.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

Cannabis Law Report

DECEMBER 6, 2021

“We look forward to Jeff’s significant contributions heading into another year of continued growth and progress for Goldfinch Bio, including a planned interim data readout from TRACTION-2, the ongoing Phase 2 clinical trial of our lead precision kidney medicine candidate, in mid-2022.”. Jacobs graduated magna cum laude with a B.S.

Research and Development 52

Research and Development Supply Chain Clinical Trials Medicine 52

The Cannigma

JULY 1, 2022

However, a result can be statistically significant but not clinically significant–meaning that even though a study may detect a difference on paper, it may make no tangible difference in real-world application. Moreover much of the research done has focused on synthetic pharmaceutical grade cannabinoids developed by pharmaceutical companies.

Research and Development 108

Research and Development Data THC Clinical Trials 108

The Cannigma

AUGUST 26, 2021

Australia has a legal medical marijuana program, and while recreational cannabis remains illegal on the federal level, the enforcement of cannabis laws and the penalties handed out can differ widely from one territory to another. Medical: Legal Recreational: Illegal (though at least one territory has adopted decriminalization).

Legalization 52

Legalization Access Medicine Clinical Trials 52

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. Leading the pilot research project is Dr. Eric Hollander, director of the Autism and Spectrum Program and Anxiety and Depression Program at Montefiore Hospital.

Research and Development 40

Research and Development Epilepsy Clinical Trials Treatment 40

CannaTech

MARCH 24, 2019

Medical cannabis is making its way out of the haze and into the headlines as expanded research programs demonstrate its proven benefits. Some of the most recognized applications of cannabinoid-based medicine are in the treatment of neuropathic pain , inflammation and muscle spasticity.

Research and Development 45

Research and Development Therapy Clinical Trials Chronic Pain 45

Cannabis Law Report

JULY 4, 2021

Cannabidiol or CBD is one of the most common cannabinoids found in cannabis. Clinical trials across the EU have also shown CBD oils and other hemp products to have a potential range of benefits. There are two different types of cannabinoid receptors in your body. What Is CBD?

THC 105

THC CBD Legalization Oil 105

The Joint Blog

APRIL 17, 2020

Over the past few decades, there has been an increased interest in leveraging cannabis and cannabinoids for medicinal purpose. Reported adverse effect in many clinical trials included amnesia, impaired balance, disturbed attention, dizziness, lethargy, and somnolence. In 2018, ProCon.org has estimated well over 3.5M

Events 48

Events THC Chronic Pain Sleep 48

The Joint Blog

OCTOBER 21, 2020

This includes cannabidiol or CBD, one of the most active cannabinoids found in the plant. Some have restrictive medical marijuana programs that only allow patients with certain conditions to have access to any cannabis medication, including marijuana and hemp. With this, hemp byproducts also began to flood the market.

CBD 36

CBD Legalization Oil Hemp 36

Puff Puff Post

NOVEMBER 5, 2019

. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. For more information, visit www.inmedpharma.com. About INM-755.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Project CBD

MAY 3, 2023

Goldstein will be leading the Medical Practicum at CannMed 2023 (May 15-17), where she will also be speaking about CBG and other minor cannabinoids during the main session. You have said that cannabigerol, or CBG, is one of your favorite cannabinoids. Is that because CBG is a precursor for the other plant cannabinoids?

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209